CORDIS
EU research results

CORDIS

English EN
Novel viral therapy through targeting DNA repair

Novel viral therapy through targeting DNA repair

Objective

Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.

Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.

Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 139 162,50

Beneficiaries (2)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 139 162,50

KAROLINSKA INSTITUTET INNOVATIONS AB

Sweden

EU Contribution

€ 10 837,50

Project information

Grant agreement ID: 755150

Status

Closed project

  • Start date

    1 July 2017

  • End date

    31 December 2018

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 150 000

  • EU contribution

    € 150 000

Hosted by:

KAROLINSKA INSTITUTET

Sweden